Le Lézard
Classified in: Health
Subjects: LAW, AVO

Kickbacks Escalate Medical Prices, according to the Journal of American Physicians and Surgeons


TUCSON, Ariz., June 13, 2018 /PRNewswire/ -- In searching for treatable causes of sky-high medical costs, both government and private entities are scrutinizing the cost of hospital supplies, writes Marilyn Singleton, M.D., J.D., in the summer issue of the Journal of American Physicians and Surgeons.  Supplies account for an average 15 percent of total costs, and as much as 40 percent.

About 97 percent of hospitals in the United States purchase through group purchasing organization (GPO) contracts, Dr Singleton writes. GPOs were intended to reduce costs. At first, they were paid through membership dues, but in the 1970s GPOs began collecting "contract administrative fees" or "rebates" from vendors. Such fees are typically based on a percentage of the costs of the products that GPO customers purchase through GPO-negotiated contracts. They are essentially kickbacks, which would be illegal under the federal healthcare programs Anti-Kickback Statute, Dr. Singleton explains, except  for "safe harbor" provisions enacted by statute or regulation.

"While there are more than 600 GPOs in various industries, only a few GPOs dominate the medical market," Dr. Singleton writes. "The current fee structure raises an obvious conflict of interest: ... since vendors pay the fees as a percentage of the product cost, the higher the price, the higher the GPOs' fees."

Safe-harbor protection is supposedly afforded only to arrangements that meet certain regulatory requirements, but government oversight is extremely limited, Dr. Singleton notes.

High prices, serious and worsening drug shortages, and stifled innovation may all be largely attributable to the favorable treatment accorded to GPOs, Dr. Singleton suggests.

"Since the federal healthcare Anti-Kickback Statute GPO exception was created 30 years ago, the landscape has changed. The current GPO funding structure's incentive is to 'negotiate' higher prices for its customers. The vendors with the most money can afford to pay the high fees and buy themselves into the game. The term 'payola'?pay to play?comes to mind. The situation is exacerbated because insurers absorb the higher prices and thus hospitals may have less incentive to monitor pricing."

Dr. Singleton concludes that "an honest look at the current state of GPOs should label the conduct illegal," but notes that "money talks." Premier, one of the five largest GPOs has 19 lobbyists and spent $1,790,000 on lobbying in 2017. It contributes to Democrat and Republican congressional committees, and to candidates of both parties.

"The time has come to do what is best for patients and to restore integrity, competition, choice, and cost savings to the purchasing process," she states.

The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS), a national organization representing physicians in all specialties since 1943.

SOURCE Association of American Physicians and Surgeons (AAPS)


These press releases may also interest you

at 11:34
At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the...

at 11:25
TimelyCare, higher education's most trusted virtual health and well-being provider, has earned recognition as one of the World's Best Digital Health Companies by Newsweek, and has been awarded five Top Workplaces Awards for culture excellence....

at 11:16
Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the first quarter 2024 on Thursday, May 2 at 9 a.m., ET. The company will issue a news release detailing its results before the market...

at 11:15
Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics, announced the approval to expand the use of vebreltinib (also referred...

at 11:10
Through its 2030 Strategic Plan, NJII plans to double the size of the organization and to exceed $70M revenue as it rolls out various new initiatives focused on accelerating technology translation, spurring innovation and upskilling workers. As...

at 11:09
ScreenPoint Medical, today announced a significant transition in its leadership as Mark Koeniguer, the current CEO, steps down from his position. Mark served as CEO since 2022 and was instrumental in ScreenPoint's commercial growth and success over...



News published on and distributed by: